Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8206 to 8217 of 8217 results

  1. New injectable immunotherapy treatment for rare form of triple negative breast cancer recommended by NICE

    People with triple negative breast cancer that has spread to other parts of the body may soon benefit from pembrolizumab in combination with chemotherapy.

  2. NICE welcomes life sciences review recommendations

    NICE’s priority is to get the best care to patients fast while ensuring value for the taxpayer.

  3. Testing could help prevent further strokes in people with gene variant

    People who have had an ischaemic stroke or transient ischaemic attack should have a genetic test to find out whether they can be treated with a drug which reduces the risk of further strokes

  4. £1.8m funding awarded to explore guidance on regulating digital mental health tools

    NICE and the MHRA have been awarded £1.8m funding by Wellcome over three years to explore and produce guidance on regulating digital mental health tools.

  5. NICE recommends a weekly injection for treating growth failure in children

    This recommendation comes from a pilot to develop simpler, faster evaluations for the appraisal of some treatments.

  6. Introducing a new way of prioritising our guidance topics

    NICE's deputy chief executive, Jonathan Benger, talks about our new approach to prioritisation.

  7. How NICE is ensuring its topic prioritisation decisions are grounded in lived experience

    Simon Denegri discusses NICE’s commitment to involving the public voice in its work and decisions.

  8. NICE collaboration on streamlined licensing and patient access process for new medicines

    Companies can now submit medicines for the new Innovative Licensing and Access Pathway (ILAP) following close collaboration between the NICE, drug regulators, the NHS and equivalent organisations in Scotland.

  9. Pembrolizumab plus chemotherapy not recommend for triple negative breast cancer

    Draft guidance published today (8 March 2022) by NICE does not recommend pembrolizumab plus chemotherapy for treating triple negative breast cancer

  10. How NICE manages the potential conflicts of interests of patient experts

    People with lived experience provide valuable insight into the impact of NICE’s’ guidance and advice.

  11. Women inspiring inclusion in NICE guidance

    This International Women’s Day, we’re focusing on the invaluable contributions of 2 of the women who help shape our guidance through their independent voluntary committee roles. They talk to us about their involvement with NICE and what #InspireInclusion means to them.

  12. NICE joins the shared commitment to public involvement in research

    Working alongside people and communities is an essential tool in helping to improve?the impact of our guidance and continuing to get the best care to people and communities, fast, while ensuring value for the taxpayer.